Federal Stem Cell Funding Blocked

August 24th, 2010 Henry McCusker No comments

A US District Court judge has temporarially blocked regulations regarding expansion of of stem cell research.  Read more…

Recombinant Human Platelet’s Orphan Drug Designation, BioMimetic Therapeutics (NASDAQ: BMTI)

August 23rd, 2010 Henry McCusker No comments

BMTI has received orphan drug designation from the FDA for its protein therapeutic, recombinant human platelet derived growth factor (rhPDGF-BB), Read more…

Phase 3 Bone Marrow Transplant Trial, Mesoblast (ASX:MSB; ADR:MBLTY)

August 23rd, 2010 Henry McCusker No comments

Australian, Mesoblast Limited (ASX:MSB; ADR:MBLTY), provided guidance on its Phase 3 bone marrow transplant program following a formal meeting with the US FDA. Read more…

Categories: Stem Cell Technology

$243 M Investment for Stem Cell Disease Teams

August 23rd, 2010 Henry McCusker No comments

California’s stem cell research funding agency will fund up to $243 M to help move therapies into clinical trials. Read more…

hNSC Breakthrough in Chronic Spinal Cord Injury, StemCells (NASDAQ: STEM)

August 20th, 2010 Henry McCusker No comments

STEM published new preclinical data demonstrating proprietary human neural stem cells to restore lost motor function in mice with chronic spinal cord injury. Read more…

Categories: Stem Cell Technology

New Business Unit, Cytovis™, International Stem Cell (OTCBB: ISCO)

August 20th, 2010 Henry McCusker No comments

ISCO.OB’s stem cell therapeutic programs focused on protective, transparent corneas (CytoCor™) in the front of the eye and the light-sensitive retinal tissue (CytoRet™) in the back of the eye will be formalized into a new business unit, Cytovis™. Read more…

$9.2 M Generated in Warrant Raise, BioTime (Amex:BTIM)

August 20th, 2010 Henry McCusker No comments

BTIM completed its warrant discount offer which generated $9,195,422 of proceeds to BTIM Read more…

New ASTM Analyst Review

August 19th, 2010 Henry McCusker No comments

The blended valuation model implies a pricing of $4.40 given the fully diluted shares outstanding. The Sum of the Parts estimation of $5.62 is discounted 10% and is significantly above this stocks current price of $1.49. Read more…

iPSCs, Potential Treatment for Parkinson’s Disease

August 19th, 2010 Henry McCusker No comments

Researchers at the Buck Institute for Age Research used induced pluripotent stem cells, or iPSCs, from humans (to treat rodents) with Parkinson’s Disease, Read more…

Categories: Stem Cell Technology

Regeneration of Injured Nerves

August 19th, 2010 Henry McCusker No comments

Researchers for the first time have induced robust regeneration of nerve tissue connections in injured adult spinal cord sites that control voluntary movement. Read more…